Instil Bio Inc: Recent Acquisition Activity and Stock Performance

Instil Bio, Inc., a clinical-stage biopharmaceutical company based in Dallas, Texas, has recently been in the spotlight due to significant investment activity. The company, which specializes in developing a cell therapy pipeline focused on autologous tumor infiltrating lymphocyte for cancer treatment, has seen BOXER CAPITAL, LLC acquire a new stake. This acquisition was reported by feeds.feedburner.com on September 28, 2024.

Instil Bio serves a global customer base and is traded on the Nasdaq stock exchange. The company’s market capitalization stands at approximately $85,462,725 USD. For more detailed information about their activities and offerings, interested parties can visit their website at www.instilbio.com .

Stock Performance Overview

The stock price of Instil Bio has experienced notable volatility over the past year. The company reached a 52-week high of $92 USD on September 12, 2024, which marked a significant increase from its 52-week low of $9.62 USD on June 19, 2024. As of the last trading day on May 8, 2025, the stock closed at $13.23 USD. This closing price indicates a decline from the peak but remains above the lowest point within the year.

Instil Bio’s focus on innovative cancer treatments continues to attract attention from investors, as evidenced by recent acquisition activities and the stock’s performance dynamics.